Treatment of type 2 diabetes mellitus in patients with chronic kidney disease

被引：3
|
作者：
Gomez-Huelgas, Ricardo [1 ]
Martinez-Castelao, Alberto [2 ]
Artola, Sara [3 ]
Gorriz, Jose Luis [2 ]
Menendez, Edelmiro [4 ]
机构：
[1] Soc Espanola Med Interna SEMI, Madrid, Spain
[2] Grp Espanol Estudio Nefropatra Diabet GEENDIAB, Soc Espanola Nefrol, Valencia, Spain
[3] Red Grp Estudio Diabet Atenc Primaria redGDPS, Girona, Spain
[4] Soc Espanola Diabet, Madrid, Spain
来源：
MEDICINA CLINICA | 2014年 / 142卷 / 02期
关键词：
Type 2 diabetes mellitus; Chronic kidney disease; Cardiovascular risk factors; Elderly;
D O I：
10.1016/j.medcli.2013.10.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) are highly prevalent chronic diseases, which represent an important public health problem and require a multidisciplinary management. T2DM is the main cause of CKD and it also causes a significant comorbidity with regard to non-diabetic nephropathy. Patients with diabetes and kidney disease represent a special risk group as they have higher morbi-mortality as well as higher risk of hypoglycemia than diabetic individuals with a normal kidney function. Treatment of T2DM in patients with CKD is controversial because of the scarcity of available evidence. The current consensus report aims to ease the appropriate selection and dosage of antidiabetic treatments as well as the establishment of safety objectives of glycemic control in patients with CKD. (C) 2013 Elsevier Espana, S.L. All rights reserved.
引用
下载
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [41] Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus
    Lessey, Gayatri
    Stavropoulos, Konstantinos
    Papademetriou, Vasilios
    VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 365 - 373
  • [42] Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus
    Rastogi, Anjay
    Weir, Matthew R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (08)
  • [43] Chronic kidney disease in type 2 diabetes mellitus patients: Comparison of KDIGO and KDOQI guidelines
    Ephraim, Richard K. D.
    Mantey, Richard
    Atombo, Stephen
    Sakyi, Samuel A.
    Fondjo, Linda A.
    Tashie, Worlanyo
    Agbodzakey, Hope
    Botchway, Felix A.
    Amankwaa, Bright
    ALEXANDRIA JOURNAL OF MEDICINE, 2018, 54 (04) : 445 - 449
  • [44] Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review
    Salukhov, Vladimir V.
    Shamkhalova, Minara S.
    Duganova, Alla, V
    TERAPEVTICHESKII ARKHIV, 2023, 95 (03): : 261 - 273
  • [45] Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Mikhail, Nasser
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 138 - 144
  • [46] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [47] Management of diabetes mellitus in patients with chronic kidney disease
    Allison J. Hahr
    Mark E. Molitch
    Clinical Diabetes and Endocrinology, 1 (1):
  • [48] Diabetes mellitus and anaemia in patients with chronic kidney disease
    Lejnieks, A.
    Kuzema, V.
    Petersons, A.
    DIABETOLOGIA, 2008, 51 : S485 - S485
  • [49] THE IMPACT OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS ON SOCIAL COST IN CHRONIC KIDNEY DISEASE PATIENTS IN ITALY
    Bellelli, S.
    Turchetti, G.
    VALUE IN HEALTH, 2014, 17 (07) : A468 - A468
  • [50] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    Wanner, Christoph
    Lachin, John M.
    Inzucchi, Silvio E.
    Fitchett, David
    Mattheus, Michaela
    George, Jyothis
    Woerle, Hans J.
    Broedl, Uli C.
    von Eynatten, Maximilian
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    CIRCULATION, 2018, 137 (02) : 119 - 129
12345